KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Common Equity (2016 - 2025)

Historic Common Equity for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $233.9 million.

  • Alnylam Pharmaceuticals' Common Equity rose 62292.14% to $233.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $233.9 million, marking a year-over-year increase of 62292.14%. This contributed to the annual value of $67.1 million for FY2024, which is 13040.55% up from last year.
  • Alnylam Pharmaceuticals' Common Equity amounted to $233.9 million in Q3 2025, which was up 62292.14% from $250.6 million recorded in Q2 2025.
  • Alnylam Pharmaceuticals' 5-year Common Equity high stood at $926.2 million for Q1 2021, and its period low was -$408.1 million during Q2 2023.
  • Moreover, its 5-year median value for Common Equity was $67.1 million (2024), whereas its average is $152.5 million.
  • Its Common Equity has fluctuated over the past 5 years, first crashed by 33183.99% in 2023, then soared by 827055.75% in 2025.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Common Equity stood at $588.2 million in 2021, then crashed by 126.9% to -$158.2 million in 2022, then tumbled by 39.45% to -$220.6 million in 2023, then soared by 130.41% to $67.1 million in 2024, then soared by 248.64% to $233.9 million in 2025.
  • Its last three reported values are $233.9 million in Q3 2025, $250.6 million for Q2 2025, and $115.4 million during Q1 2025.